The latest price target for BeiGene (NASDAQ: BGNE) was reported by Citigroup on September 21, 2023. The analyst firm set a price target for $290.00 expecting BGNE to rise to within 12 months (a possible 52.17% upside). 21 analyst firms have reported ratings in the last year.

The latest analyst rating for BeiGene (NASDAQ: BGNE) was provided by Citigroup, and BeiGene maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BeiGene, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BeiGene was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.

While ratings are subjective and will change, the latest BeiGene (BGNE) rating was a maintained with a price target of $285.00 to $290.00. The current price BeiGene (BGNE) is trading at is $190.58, which is out of the analyst’s predicted range.

The latest price target for BeiGene (NASDAQ: BGNE) was reported by Citigroup on September 21, 2023. The analyst firm set a price target for $290.00 expecting BGNE to rise to within 12 months (a possible 52.17% upside). 21 analyst firms have reported ratings in the last year.

The latest analyst rating for BeiGene (NASDAQ: BGNE) was provided by Citigroup, and BeiGene maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BeiGene, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BeiGene was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.

While ratings are subjective and will change, the latest BeiGene (BGNE) rating was a maintained with a price target of $285.00 to $290.00. The current price BeiGene (BGNE) is trading at is $190.58, which is out of the analyst’s predicted range.

The latest price target for BeiGene (NASDAQ: BGNE) was reported by Citigroup on September 21, 2023. The analyst firm set a price target for $290.00 expecting BGNE to rise to within 12 months (a possible 52.17% upside). 21 analyst firms have reported ratings in the last year.

The latest analyst rating for BeiGene (NASDAQ: BGNE) was provided by Citigroup, and BeiGene maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BeiGene, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BeiGene was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.

While ratings are subjective and will change, the latest BeiGene (BGNE) rating was a maintained with a price target of $285.00 to $290.00. The current price BeiGene (BGNE) is trading at is $190.58, which is out of the analyst’s predicted range.

The latest price target for BeiGene (NASDAQ: BGNE) was reported by Citigroup on September 21, 2023. The analyst firm set a price target for $290.00 expecting BGNE to rise to within 12 months (a possible 52.17% upside). 21 analyst firms have reported ratings in the last year.

The latest analyst rating for BeiGene (NASDAQ: BGNE) was provided by Citigroup, and BeiGene maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BeiGene, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BeiGene was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.

While ratings are subjective and will change, the latest BeiGene (BGNE) rating was a maintained with a price target of $285.00 to $290.00. The current price BeiGene (BGNE) is trading at is $190.58, which is out of the analyst’s predicted range.

The latest price target for BeiGene (NASDAQ: BGNE) was reported by Citigroup on September 21, 2023. The analyst firm set a price target for $290.00 expecting BGNE to rise to within 12 months (a possible 52.17% upside). 21 analyst firms have reported ratings in the last year.

The latest analyst rating for BeiGene (NASDAQ: BGNE) was provided by Citigroup, and BeiGene maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BeiGene, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BeiGene was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.

While ratings are subjective and will change, the latest BeiGene (BGNE) rating was a maintained with a price target of $285.00 to $290.00. The current price BeiGene (BGNE) is trading at is $190.58, which is out of the analyst’s predicted range.

The latest price target for BeiGene (NASDAQ: BGNE) was reported by Citigroup on September 21, 2023. The analyst firm set a price target for $290.00 expecting BGNE to rise to within 12 months (a possible 52.17% upside). 21 analyst firms have reported ratings in the last year.

The latest analyst rating for BeiGene (NASDAQ: BGNE) was provided by Citigroup, and BeiGene maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BeiGene, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BeiGene was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.

While ratings are subjective and will change, the latest BeiGene (BGNE) rating was a maintained with a price target of $285.00 to $290.00. The current price BeiGene (BGNE) is trading at is $190.58, which is out of the analyst’s predicted range.

The latest price target for BeiGene (NASDAQ: BGNE) was reported by Citigroup on September 21, 2023. The analyst firm set a price target for $290.00 expecting BGNE to rise to within 12 months (a possible 52.17% upside). 21 analyst firms have reported ratings in the last year.

The latest analyst rating for BeiGene (NASDAQ: BGNE) was provided by Citigroup, and BeiGene maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BeiGene, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BeiGene was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.

While ratings are subjective and will change, the latest BeiGene (BGNE) rating was a maintained with a price target of $285.00 to $290.00. The current price BeiGene (BGNE) is trading at is $190.58, which is out of the analyst’s predicted range.

The latest price target for BeiGene (NASDAQ: BGNE) was reported by Citigroup on September 21, 2023. The analyst firm set a price target for $290.00 expecting BGNE to rise to within 12 months (a possible 52.17% upside). 21 analyst firms have reported ratings in the last year.

The latest analyst rating for BeiGene (NASDAQ: BGNE) was provided by Citigroup, and BeiGene maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BeiGene, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BeiGene was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.

While ratings are subjective and will change, the latest BeiGene (BGNE) rating was a maintained with a price target of $285.00 to $290.00. The current price BeiGene (BGNE) is trading at is $190.58, which is out of the analyst’s predicted range.